4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells

While chimeric antigen receptor-modified T (CAR-T) cells have shown great success for the treatment of B cell leukemia, their efficacy appears to be compromised in B cell derived lymphoma and solid tumors. Optimization of the CAR design to improve persistence and cytotoxicity is a focus of the curre...

全面介紹

書目詳細資料

發表在:	Frontiers in Immunology
Main Authors:	Qiang Dai, Ping Han, Xinyue Qi, Fanlin Li, Min Li, Lilv Fan, Huihui Zhang, Xiaoqing Zhang, Xuanming Yang
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2020-11-01
主題:	4-1BB chimeric antigen receptor-modified T lymphoma immunotherapy CD20
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.539654/full